Radient Pharmaceuticals' Onko-Sure(R) Cancer Test Available Through NeoloMed BioSciences
12 Aug 2011
Collaborate
TUSTIN, CA--(Marketwire - August 11, 2011) - Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC) (PINKSHEETS: RXPC), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has signed a lab partner agreement with New Jersey-based diagnostics laboratory, NeoloMed BioSciences Inc.
Onko-Sure® is a non-invasive cancer blood test which has received FDA clearance for colorectal cancer monitoring during treatment and for post-treatment recurrence monitoring. Onko-Sure® has also received regulatory approval outside of the US as a general cancer tumor marker, as well as for lung cancer detection, treatment and recurrence monitoring.
Within the next two weeks, NeoloMed BioSciences will begin offering Radient's Onko-Sure® cancer test to its networks of physicians' offices and hospitals in its region including New Jersey, Connecticut, Delaware, Pennsylvania, Washington, D.C., Virginia, and Maryland. NeoloMed BioSciences is a CLIA certified and CAP accredited, consultative clinical testing laboratory. The lab's services range from routine patient testing with a focus on oncology-related indications, to more specialized testing. NeoloMed BioSicences' customers include physicians and their patients, hospitals and managed care plans, pharmaceutical and biotechnology companies, and contract clinical research organizations. NeoloMed BioSciences has been offering flow cytometry, karyotype, and FISH analysis oncology tests. Onko-Sure® is the first cancer blood test that NeoloMed will integrate into its oncology diagnostics offerings.
NeoloMed's CEO, Dr. Faribouz Payvandi, commented, "We have been looking to expand our menu of oncology diagnostics that provide valuable information for doctors and their patients. Onko-Sure® is the first blood test we've chosen to offer. Backed by compelling published clinical data and FDA clearance, we believe it will provide a very beneficial new diagnostic tool for doctors tracking disease treatment and recurrence for their colorectal cancer patients."
"Our goal is to significantly expand the availability of Onko-Sure® throughout the US and to work with regional and national diagnostics labs in doing so. We are pleased to work with NeoloMed BioSciences, which is focused in oncology diagnostics and serves a region in which we seek greater market penetration," stated Radient Chairman and CEO, Mr. Douglas MacLellan.
For more information regarding NeoloMed BioSciences, please visit .
For additional information on Radient Pharmaceuticals Corporation and its products visit: or e-mail info@radient-pharma.com. For Investor Relations contact Dilek Mir at: ir@radient-pharma.com or 714-881-0244.
The following table is intended to provide the latest information on Radient's business metrics.
----------------------------------------------------------------------------
RPC's Business Metrics
----------------------------------------------------------------------------
Cash on hand: $940,000*
*Approximate amount as of August 10,2011
----------------------------------------------------------------------------
Shares Outstanding: 198 million*
*Approximate number as of August 10, 2011 and there are 200 million shares
fully authorized.
----------------------------------------------------------------------------
Outstanding Warrants & Options: 111 million*
*Approximate number as of August 10, 2011
----------------------------------------------------------------------------
About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its FDA-cleared In Vitro Diagnostic Onko-Sure® cancer test kit for colorectal cancer treatment and recurrence monitoring. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that will help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence. To learn more about our company, products, and potentially life-saving cancer test, visit .
Forward-Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.
Digg this Bookmark with del.icio.us Add to Newsvine
Technorati:
in vitro diagnostics
oncology
cancer
labs
clinical reference labs
CLIA
colorectral cancer
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.